학술논문
AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Document Type
Article
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S255-S255
Subject
Language
ISSN
2152-2650